Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Get Free Report) insider Darren Sherman acquired 2,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were bought at an average cost of $5.33 per share, for a total transaction of $10,660.00. Following the completion of the acquisition, the insider owned 2,000 shares of the company’s stock, valued at approximately $10,660. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Darren Sherman also recently made the following trade(s):
- On Monday, August 3rd, Darren Sherman sold 15,000 shares of Orchestra BioMed stock. The stock was sold at an average price of $4.09, for a total transaction of $61,350.00.
- On Monday, June 1st, Darren Sherman sold 15,000 shares of Orchestra BioMed stock. The stock was sold at an average price of $3.87, for a total transaction of $58,050.00.
Orchestra BioMed Stock Up 1.4%
OBIO opened at $5.18 on Friday. The company has a market cap of $311.32 million, a PE ratio of -6.09 and a beta of 0.50. Orchestra BioMed Holdings, Inc. has a twelve month low of $2.20 and a twelve month high of $5.78. The company has a 50-day moving average price of $4.29 and a 200 day moving average price of $4.21. The company has a quick ratio of 8.24, a current ratio of 8.26 and a debt-to-equity ratio of 1.80.
Institutional Investors Weigh In On Orchestra BioMed
Several hedge funds and other institutional investors have recently made changes to their positions in OBIO. Rice Hall James & Associates LLC acquired a new position in Orchestra BioMed during the second quarter worth $1,830,000. Flat Footed LLC purchased a new stake in Orchestra BioMed in the 2nd quarter valued at $1,084,670. Simplify Asset Management Inc. acquired a new stake in shares of Orchestra BioMed in the 1st quarter worth $932,000. 683 Capital Management LLC acquired a new stake in shares of Orchestra BioMed in the 4th quarter worth $847,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Orchestra BioMed during the 2nd quarter worth $2,771,000. Institutional investors and hedge funds own 53.20% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts recently commented on OBIO shares. B. Riley Financial dropped their price target on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Orchestra BioMed in a report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and set a $10.00 target price (up from $9.00) on shares of Orchestra BioMed in a research note on Tuesday, August 11th. Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Barclays increased their target price on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.00.
View Our Latest Analysis on OBIO
Orchestra BioMed Company Profile
Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.
Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.
Read More
- Five stocks we like better than Orchestra BioMed
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
